{"drugs":["Linagliptin","Tradjenta"],"mono":{"0":{"id":"929895-s-0","title":"Generic Names","mono":"Linagliptin"},"1":{"id":"929895-s-1","title":"Dosing and Indications","sub":[{"id":"929895-s-1-4","title":"Adult Dosing","mono":"<ul><li>should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis<\/li><li><b>Type 2 diabetes mellitus:<\/b> take 5 mg ORALLY once daily with or without food<\/li><li><b>Type 2 diabetes mellitus:<\/b> when administered with a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin may be required<\/li><\/ul>"},{"id":"929895-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established in pediatric patients "},{"id":"929895-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal insufficiency:<\/b> no dosage adjustment is necessary<\/li><li><b>hepatic impairment:<\/b> no dosage adjustment is necessary<\/li><li><b>geriatrics:<\/b> no dosage adjustment is necessary<\/li><\/ul>"},{"id":"929895-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Type 2 diabetes mellitus<br\/>"}]},"3":{"id":"929895-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929895-s-3-9","title":"Contraindications","mono":"history of hypersensitivity to linagliptin (eg, anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity) <br\/>"},{"id":"929895-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- acute pancreatitis, including fatalities, has been reported; monitoring recommended and if suspected, immediately discontinue use<\/li><li>Immunologic:<\/li><li>-- serious hypersensitivity reactions have been reported, including anaphylaxis, angioedema, and exfoliative skin conditions; if suspected, discontinue use<\/li><li>Other:<\/li><li>-- history of angioedema to another dipeptidyl peptidase-4 (DPP-4) inhibitor; use with caution<\/li><li>Concomitant use:<\/li><li>-- insulin secretagogue (eg, sulfonylurea) or insulin may increase risk of hypoglycemia; therefore, a lower dose of sulfonylurea or insulin may be required<\/li><\/ul>"},{"id":"929895-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"929895-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929895-s-4","title":"Drug Interactions","sub":{"1":{"id":"929895-s-4-14","title":"Major","mono":"<ul><li>Amisulpride (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Balofloxacin (theoretical)<\/li><li>Besifloxacin (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Enoxacin (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Fleroxacin (theoretical)<\/li><li>Flumequine (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Lanreotide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lomefloxacin (theoretical)<\/li><li>Lurasidone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nadifloxacin (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazufloxacin (theoretical)<\/li><li>Pefloxacin (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Prulifloxacin (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Rufloxacin (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tosufloxacin (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},"2":{"id":"929895-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Esmolol (probable)<\/li><li>Furazolidone (probable)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Labetalol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Linezolid (probable)<\/li><li>Methylene Blue (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moclobemide (probable)<\/li><li>Nadolol (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nialamide (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Phenelzine (probable)<\/li><li>Pindolol (probable)<\/li><li>Practolol (probable)<\/li><li>Procarbazine (probable)<\/li><li>Propranolol (probable)<\/li><li>Rasagiline (probable)<\/li><li>Selegiline (probable)<\/li><li>Sotalol (probable)<\/li><li>Timolol (probable)<\/li><li>Tranylcypromine (probable)<\/li><\/ul>"}}},"5":{"id":"929895-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypoglycemia (monotherapy, 6.6%; combination therapy, 22.9%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Pancreatic cancer, Pancreatitis<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Other:<\/b>Angioedema, Pancreatic cancer<\/li><\/ul>"},"6":{"id":"929895-s-6","title":"Drug Name Info","sub":{"0":{"id":"929895-s-6-17","title":"US Trade Names","mono":"Tradjenta<br\/>"},"2":{"id":"929895-s-6-19","title":"Class","mono":"<ul><li>Dipeptidyl Peptidase IV Inhibitor<\/li><li>Hypoglycemic<\/li><\/ul>"},"3":{"id":"929895-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929895-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929895-s-7","title":"Mechanism Of Action","mono":"Linagliptin is a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, which exerts its activity in patients with type 2 diabetes mellitus by protecting the endogenous incretin hormones and enhancing their actions. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are incretin hormones released throughout the day at a low basal level, and at increased levels in response to meal intake, to maintain glucose homeostasis. However, GLP and GLP-1 are metabolized rapidly by DPP-4 enzyme, resulting in loss of insulinotropic effects. Linagliptin inhibits the degradation of incretin hormones by DPP-4, thereby increasing insulin release in a glucose-dependent manner and decreasing the levels of circulating glucagon.<br\/>"},"8":{"id":"929895-s-8","title":"Pharmacokinetics","sub":[{"id":"929895-s-8-23","title":"Absorption","mono":"<ul><li>Tmax: 1.5 hours<\/li><li>Bioavailability, oral: 30%<\/li><li>Effect of food: not clinically relevant<\/li><\/ul>"},{"id":"929895-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 1110 L<\/li><li>Protein binding: 70% to 99%<\/li><\/ul>"},{"id":"929895-s-8-25","title":"Metabolism","mono":"limited <br\/>"},{"id":"929895-s-8-26","title":"Excretion","mono":"<ul><li>Renal clearance: 70 mL\/min<\/li><li>Renal excretion: 5% to less than 7%<\/li><li>Bile: 80%<\/li><li>Extracorporeal: no (hemodialysis), no (peritoneal dialysis)<\/li><\/ul>"},{"id":"929895-s-8-27","title":"Elimination Half Life","mono":"greater than 100 hours <br\/>"}]},"9":{"id":"929895-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>may be taken with or without food <br\/>"},"10":{"id":"929895-s-10","title":"Monitoring","mono":"<ul><li>achieving glycemic control, including meeting HbA1c goal is indicative of efficacy<\/li><li>HbA1c; twice yearly in patients who are meeting treatment goals; every 3 months in patients whose therapy has changed and\/or who are not meeting glycemic goals; more frequently as clinically warranted<\/li><li>blood glucose (self-monitoring); as needed to assist in meeting goals of therapy  and periodically to manage hypoglycemia<\/li><\/ul>"},"11":{"id":"929895-s-11","title":"How Supplied","mono":"<b>Tradjenta<\/b><br\/>Oral Tablet: 5 MG<br\/>"},"13":{"id":"929895-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report symptoms of acute pancreatitis (persistent severe abdominal pain that may radiate to the back, which may or may not be accompanied by vomiting) and to promptly discontinue drug if symptoms occur.<\/li><li>Drug may cause arthralgia, back pain, headache, hypoglycemia, and nasopharyngitis.<\/li><li>Advise diabetic patients to monitor for signs\/symptoms of hypoglycemia and to report difficulties with glycemic control.<\/li><li>Instruct patients to report periods of stress, such as fever, trauma, infection, or surgery.<\/li><li>May be taken with or without food.<\/li><li>If a dose is missed, do not double next dose.<\/li><\/ul>"}}}